ALZN002 (autologous DCs pulsed with E22W mutant peptide). + Placebo
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer Disease
Conditions
Alzheimer Disease
Trial Timeline
Jul 5, 2023 → Mar 3, 2028
NCT ID
NCT05834296About ALZN002 (autologous DCs pulsed with E22W mutant peptide). + Placebo
ALZN002 (autologous DCs pulsed with E22W mutant peptide). + Placebo is a phase 1/2 stage product being developed by Alzamend Neuro for Alzheimer Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05834296. Target conditions include Alzheimer Disease.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer Disease were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
9
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05834296 | Phase 1/2 | Active |
Competing Products
20 competing products in Alzheimer Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 2 | 21 |
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 32 |
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| Zagotenemab + Placebo | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo + LY3202626 | Eli Lilly | Phase 2 | 35 |
| Donanemab + Placebo | Eli Lilly | Phase 3 | 47 |
| GSK4527226 | Alector | Phase 2 | 29 |
| AL002 + Placebo | Alector | Phase 2 | 25 |
| GSK4527226 | Alector | Phase 2 | 32 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| donanemab | Eli Lilly | Phase 2 | 35 |
| ATH-1017 | LeonaBio | Phase 2/3 | 20 |
| ATH-1017 + Placebo | LeonaBio | Phase 2/3 | 28 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 25 |
| NDX-1017 + Placebo | LeonaBio | Phase 1 | 19 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 19 |